BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu L, Shah SS, Naini BV, French S, Wu T, Torbenson MS, Chandan VS. Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas. American Journal of Surgical Pathology 2016;40:1062-9. [DOI: 10.1097/pas.0000000000000624] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Miyazaki M. What is a predictive role of acute-phase serum Amyloid in the prognosis of patients with hepatocellular carcinoma? J Invest Surg 2022;:1-2. [PMID: 35410565 DOI: 10.1080/08941939.2022.2045398] [Reference Citation Analysis]
2 Joseph NM, Blank A, Shain AH, Gill RM, Umetsu SE, Shafizadeh N, Torbenson MS, Kakar S. Hepatocellular Neoplasms with Loss of Liver Fatty Acid Binding Protein: Clinicopathologic Features and Molecular Profiling. Human Pathology 2022. [DOI: 10.1016/j.humpath.2022.01.007] [Reference Citation Analysis]
3 Kim H, Park YN. Hepatocellular adenomas: recent updates. J Pathol Transl Med 2021;55:171-80. [PMID: 33823565 DOI: 10.4132/jptm.2021.02.27] [Reference Citation Analysis]
4 Yasir S, Chen ZE, Jain D, Kakar S, Wu TT, Yeh MM, Torbenson MS. Hepatic Adenomas in Patients 60 and Older Are Enriched forHNF1AInactivation and Malignant Transformation. Am J Surg Pathol 2022. [PMID: 35383587 DOI: 10.1097/PAS.0000000000001892] [Reference Citation Analysis]